Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14909183 | 0.77 | KDM4E (0.39) | ATRPOLBTDP1LMNASMN1; SMN2 | |
| SCHEMBL1350020 | 0.76 | ATR (0.34) | ATRPOLBLMNASMN1; SMN2 | |
| SCHEMBL238763 | 0.74 | SMN1; SMN2 (0.46) | POLBTDP1LMNASMN1; SMN2 | |
| SCHEMBL6615497 | 0.72 | CHRM2 (0.36) | POLB | |
| SCHEMBL1699332 | 0.71 | ATR (0.36) | ATRFFAR1TDP1LMNASMN1; SMN2 | |
| SCHEMBL236945 | 0.68 | CCR1 (0.34) | ATRLMNASMN1; SMN2 | |
| SCHEMBL27001778 | 0.67 | RECQL (0.35) | FFAR1TDP1LMNASMN1; SMN2 | |
| SCHEMBL3770744 | 0.66 | LMNA (0.33) | LMNASMN1; SMN2 | |
| SCHEMBL27193312 | 0.66 | CNR2 (0.32) | — | |
| SCHEMBL23931107 | 0.65 | GRM5 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235867-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2004-11-25 | — | — | US | disclosed |
| WO-2003009852-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235867-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | ATR 708/4885POLB 2548/4885FFAR1 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.